Latest Hotspot

AbbVie Seeks FDA and EMA Approval for Upadacitinib (RINVOQ®) to Treat Giant Cell Arteritis

17 July 2024
3 min read

AbbVie revealed that it has filed applications with the U.S. Food and Drug Administration and the European Medicines Agency to approve a new use for upadacitinib (RINVOQ; 15 mg, once daily) aimed at the treatment of adult patients afflicted with giant cell arteritis.

👇Discover comprehensive information about this drug, from its R&D status, core patents, clinical trials to approval status in global countries, by simply clicking on the image below. Dive deep into our drug database now.

"At present, there are limited approved therapies for individuals with GCA. The majority of patients rely on glucocorticoids, yet many struggle to cease their use without experiencing a resurgence of GCA symptoms," said Roopal Thakkar, M.D., executive vice president of research and development and chief scientific officer at AbbVie. "We understand the significance of sustaining remission while minimizing glucocorticoid usage in GCA."

The submissions to both the FDA and EMA are backed by earlier results from the SELECT-GCA Phase 3 trial, which investigates the safety and effectiveness of upadacitinib in GCA patients.

SELECT-GCA is a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to assess the safety and efficacy of upadacitinib in 428 GCA patients. The trial includes two phases. The initial phase compared the efficacy of upadacitinib combined with a 26-week corticosteroid taper to a placebo combined with a 52-week corticosteroid taper.

Moreover, the initial phase also evaluated the safety and tolerability of upadacitinib in these patients. The ongoing second phase is assessing the safety and efficacy of continuing versus discontinuing upadacitinib in maintaining remission among participants who achieved sustained remission during the first phase.

Developed by AbbVie researchers, RINVOQ is a JAK inhibitor being explored for multiple immune-mediated inflammatory conditions. Enzymatic and cellular assays showed RINVOQ has higher inhibitory potency for JAK-1 vs JAK-2, JAK-3, and TYK-2.

The clinical relevance of inhibiting specific JAK enzymes for therapeutic efficacy and safety remains unknown. Upadacitinib is under investigation in Phase 3 trials for conditions including alopecia areata, giant cell arteritis, hidradenitis suppurativa, Takayasu arteritis, systemic lupus erythematosus, and vitiligo. Upadacitinib is not yet approved for use in giant cell arteritis, and its safety and efficacy for this condition have not been confirmed by regulatory bodies.

👇Explore the latest research progress on drug-related developments, indications, therapeutic organizations, clinical trials, results, and patents by clicking on the targeted picture link below. Unfold a world of comprehensive information on this target in just a click!

According to the data provided by the Synapse Database, As of July 17, 2024, there are 8 investigational drugs for the  JAK-1 vs JAK-2, JAK-3, and TYK-2 target, including 55 indications, 19 R&D institutions involved, with related clinical trials reaching 252, and as many as 1470 patents.

Upadacitinib shows promising potential in treating a wide range of diseases affecting different body systems, making it a valuable addition to the pharmaceutical market. Upadacitinib received its first approval in the United States in August 2019 and has since been granted Priority Review, Orphan Drug, Breakthrough Therapy, and Special Review Project designations. It is currently in the highest phase of development globally and in China.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Is Atogepant approved by the FDA?
Drug Insights
2 min read
Is Atogepant approved by the FDA?
17 July 2024
atogepant is FDA approved. Atogepant, marketed under the brand name Qulipta, received FDA approval on September 28, 2021.
Read →
The initial participant has received a dose in the Phase I clinical study of YOLT-201
Latest Hotspot
3 min read
The initial participant has received a dose in the Phase I clinical study of YOLT-201
17 July 2024
YolTech Therapeutics has announced the successful enrollment of the inaugural patient in the Phase I clinical trial of YOLT-201.
Read →
Is Tisotumab vedotin approved by the FDA?
Drug Insights
4 min read
Is Tisotumab vedotin approved by the FDA?
17 July 2024
Tisotumab vedotin (Tivdak) received accelerated approval from the US Food and Drug Administration (FDA) on September 20, 2021.
Read →
The initial participant enrolled in a Phase 2 trial of Olatec's dapansutrile for Type 2 diabetes patients
Latest Hotspot
3 min read
The initial participant enrolled in a Phase 2 trial of Olatec's dapansutrile for Type 2 diabetes patients
17 July 2024
Olatec Therapeutics, Inc., a pioneer in the field of selective NLRP3 inhibitors, revealed that individuals with type 2 diabetes mellitus and associated diabetic complications are currently being recruited
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.